AXP vs BOLT · P/E 20, rev $21.73B vs rev $31.0K
American Express Company (AXP) versus Bolt Biotherapeutics (BOLT) — a side-by-side from cached financials, not a winner call.
American Express Company (AXP) is a credit services company listed on US.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Latest reported AXP revenue for 2026-06-30 was $21.73B. Net income was $6.08B. AXP currently screens at market cap $215.94B and trailing P/E 19.8.
Latest reported BOLT revenue for 2026-06-30 was $31.0K. Net income was -$15.0M. Revenue was up 19.2% from 2026-03-31 to 2026-06-30. BOLT currently screens at market cap $11.3M.
AXP currently screens at market cap $215.94B and trailing P/E 19.8. BOLT currently screens at market cap $11.3M.
Not investment advice. Open the AXP and BOLT stock pages for the full models.
Not investment advice.